Chronic Treatment with the 5-HT1A Receptor Partial Agonist Tandospirone Increases Hippocampal Neurogenesis

Neurology and Therapy

Volumn 3, Issue 1, 2014, Pages 67-77

  Mori, Masayoshi ^a   Murata, Yusuke ^a   Matsuo, Asami ^a   Takemoto, Tomoyo ^a   Mine, Kazunori ^b  

^a FUKUOKA UNIVERSITY   (Japan)

^b Mito Hospital   (Japan)

Author keywords

5 HT1A receptor partial agonist; Chronic treatment; Clinical efficacy; Depression and anxiety; Dose dependent; Doublecortin; Hippocampal neurogenesis; Novelty suppressed feeding; Tandospirone

Indexed keywords

SEROTONIN 1A RECEPTOR; TANDOSPIRONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; CONTROLLED STUDY; DENTATE GYRUS; DEPRESSION; DRUG EFFECT; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; LATENT PERIOD; MALE; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; NOVELTY SUPPRESSED FEEDING TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 84977107038     PISSN: 21938253     EISSN: 21936536     Source Type: Journal    
DOI: 10.1007/s40120-013-0015-0     Document Type: Article

References (49)

1. Klenk MM, Strauman TJ, Higgins ET. Regulatory focus and anxiety: a self-regulatory model of GAD-depression comorbidity. Pers Individ Differ. 2011;50:935–43.
2. Kato M, Chang CM. Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression. CNS Drugs. 2013;27(Suppl 1):S11–9.
3. Trivedi HM, Fava M, Wisniewski RS, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354:1243–52.
4. Rush AJ. Limitations in efficacy of antidepressant monotherapy. J Clin Psychiatry. 2007;68(Suppl 10):8–10.
5. Li X, Frye MA, Shelton RC. Review of pharmacological treatment in mood disorders and future directions for drug development. Neuropsychopharmacology. 2012;37:77–101.
6. Baldwin D, Woods R, Lawson R, Taylor D. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ. 2011;342:d1199.
7. Petrik D, Lagace DC, Eisch AJ. The neurogenesis hypothesis of affective and anxiety disorders: are we mistaking the scaffolding for the building? Neuropharmacology. 2012;62:21–34.
8. Eriksson PS, Perfilieva E, Björk-Eriksson T, et al. Neurogenesis in the adult human hippocampus. Nat Med. 1998;4:1313–7.
9. Gould E, Gross CG. Neurogenesis in adult mammals: some progress and problems. J Neurosci. 2002;22:619–23.
10. Gould E, Tanapat P, McEwen BS, Flügge G, Fuchs E. Proliferation of granule cell precursors in the dentate gyrus of adult monkeys is diminished by stress. Proc Natl Acad Sci USA. 1998;95:3168–71.
11. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci. 2000;20:9104–10.
12. Fuchs E, Flügge G. Stress, glucocorticoids and structural plasticity of the hippocampus. Neurosci Biobehav Rev. 1998;23:295–300.
13. Samuels BA, Hen R. Neurogenesis and affective disorders. Eur J Neurosci. 2011;33:1152–9.
14. Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry. 2003;53:193–203.
15. Polter AM, Li X. 5-HT1A receptor-regulated signal transduction pathways in brain. Cell Signal. 2010;22:1406–12.
16. Davidson JR. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry. 2010;71(Suppl E1):e04.
17. Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry. 2004;65(Suppl 5):7–12.
18. Chamberlain SR, Müller U, Deakin JB, et al. Lack of deleterious effects of buspirone on cognition in healthy male volunteers. J Psychopharmacol. 2007;21:210–5.
19. Lader M, Tylee A, Donoghue J. Withdrawing benzodiazepines in primary care. CNS Drugs. 2009;23:19–34.
20. Okamoto R, Itoh Y, Murata Y, Kobayashi D, Hosoi M, Mine K. Reduction of group II metabotropic glutamate receptors during development of benzodiazepine dependence. Pharmacology. 2013;91:145–52.
21. Suzuki M, Uchiumi M, Murasaki M. Effects of tandospirone, a 5-HT1A receptor-related anxiolytic, on daytime sleepiness and psychomotor functions: a comparative double-blind study with diazepam. Yakubutsu Seishin Kodo. 1993;13:213–24.
22. Evans SM, Troisi JR 2nd, Griffiths RR. Tandospirone and alprazolam: comparison of behavioral effects and abuse liability in humans. J Pharmacol Exp Ther. 1994;271:683–94.
23. Nishitsuji K, To H, Shimizu T, et al. The pharmacokinetics and pharmacodynamics of tandospirone in rats exposed to conditioned fear stress. Eur Neuropsychopharmacol. 2006;16:376–82.
24. Wu X, Castrén E. Co-treatment with diazepam prevents the effects of fluoxetine on the proliferation and survival of hippocampal dentate granule cells. Biol Psychiatry. 2009;66:5–8.
25. Sun Y, Evans J, Russell B, Kydd R, Connor B. A benzodiazepine impairs the neurogenic and behavioural effects of fluoxetine in a rodent model of chronic stress. Neuropharmacology. 2013;72:20–8.
26. Yamada K, Yagi G, Kanba S. Clinical efficacy of tandospirone augmentation in patients with major depressive disorder: a randomized controlled trial. Psychiatry Clin Neurosci. 2003;57:183–7.
27. Artigas F. Serotonin receptors involved in antidepressant effects. Pharmacol Ther. 2013;137:119–31.
28. Nishitsuji K, To H, Murakami Y, et al. Tandospirone in the treatment of generalised anxiety disorder and mixed anxiety–depression: results of a comparatively high dosage trial. Clin Drug Investig. 2004;24:121–6.
29. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301:805–9.
30. Banasr M, Hery M, Printemps R, Daszuta A. Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone. Neuropsychopharmacology. 2004;29:450–60.
31. Soumier A, Banasr M, Goff LK, Daszuta A. Region- and phase-dependent effects of 5-HT(1A) and 5-HT(2C) receptor activation on adult neurogenesis. Eur Neuropsychopharmacol. 2010;20:336–45.
32. Radley JJ, Jacobs BL. 5-HT1A receptor antagonist administration decreases cell proliferation in the dentate gyrus. Brain Res. 2002;955:264–7.
33. Sullivan NR, Crane JW, Damjanoska KJ, et al. Tandospirone activates neuroendocrine and ERK (MAP kinase) signaling pathways specifically through 5-HT1A receptor mechanisms in vivo. Naunyn Schmiedebergs Arch Pharmacol. 2005;371:18–26.
34. Bodnoff SR, Suranyi-Cadotte B, Aitken DH, Quirion R, Meaney MJ. The effects of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacology. 1988;95:298–302.
35. Bodnoff SR, Suranyi-Cadotte B, Quirion R, Meaney MJ. A comparison of the effects of diazepam versus several typical and atypical anti-depressant drugs in an animal model of anxiety. Psychopharmacology. 1989;97:277–9.
36. Marcussen AB, Flagstad P, Kristjansen PE, Johansen FF, Englund U. Increase in neurogenesis and behavioural benefit after chronic fluoxetine treatment in Wistar rats. Acta Neurol Scand. 2008;117:94–100.
37. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 6th ed. New York: Academic Press; 2007.
38. West MJ, Gundersen HJ. Unbiased stereological estimation of the number of neurons in the human hippocampus. J Comp Neurol. 1990;296:1–22.
39. Rao MS, Shetty AK. Efficacy of doublecortin as a marker to analyse the absolute number and dendritic growth of newly generated neurons in the adult dentate gyrus. Eur J Neurosci. 2004;19:234–46.
40. Couillard-Despres S, Winner B, Schaubeck S, et al. Doublecortin expression levels in adult brain reflect neurogenesis. Eur J Neurosci. 2005;21:1–14.
41. Tamai H, Komaki G, Kubota S, et al. The clinical efficacy of a 5-HT1A agonist, SM-3997, in the treatment of bulimia. Int J Obes. 1990;14:289–92.
42. Wilcox CS, Ferguson JM, Dale JL, Heiser JF. A double-blind trial of low- and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients. Psychopharmacol Bull. 1996;32:335–42.
43. Sato S, Mizukami K, Asada T. A preliminary open-label study of 5-HT1A partial agonist tandospirone for behavioural and psychological symptoms associated with dementia. Int J Neuropsychopharmacol. 2007;10:281–3.
44. Ohno Y. Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson’s disease. CNS Neurosci Ther. 2011;17:58–65.
45. Lacivita E, Di Pilato P, De Giorgio P, et al. The therapeutic potential of 5-HT1A receptors: a patent review. Expert Opin Ther Pat. 2012;22:887–902.
46. Celada P, Bortolozzi A, Artigas F. Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs. 2013;27:703–16.
47. Enciu AM, Nicolescu MI, Manole CG, Mureşanu DF, Popescu LM, Popescu BO. Neuroregeneration in neurodegenerative disorders. BMC Neurol. 2011;11:75.
48. Barbarich-Marsteller NC, Fornal CA, Takase LF, et al. Activity-based anorexia is associated with reduced hippocampal cell proliferation in adolescent female rats. Behav Brain Res. 2013;236:251–7.
49. Snyder JS, Soumier A, Brewer M, Pickel J, Cameron HA. Adult hippocampal neurogenesis buffers stress responses and depressive behaviour. Nature. 2011;476:458–61.